EMC
MCID: EPT010
MIFTS: 55

Epithelial-Myoepithelial Carcinoma (EMC)

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Epithelial-Myoepithelial Carcinoma

MalaCards integrated aliases for Epithelial-Myoepithelial Carcinoma:

Name: Epithelial-Myoepithelial Carcinoma 12 73 20 15 39 70
Clear Cell Adenoma 20 70
Epithelial Myoepithelial Carcinoma 20
Glycogen-Rich Adenocarcinoma 20
Monomorphic Clear Cell Tumor 20
Adenocarcinoma, Clear Cell 70
Glycogen-Rich Adenoma 20
Tubular Solid Adenoma 20
Adenomyo-Epithelioma 20
Clear Cell Carcinoma 20
Emc 20

Classifications:



External Ids:

Disease Ontology 12 DOID:5309
NCIt 50 C4199
SNOMED-CT 67 189722008
UMLS 70 C0206681 C0334315 C0334392

Summaries for Epithelial-Myoepithelial Carcinoma

MalaCards based summary : Epithelial-Myoepithelial Carcinoma, also known as clear cell adenoma, is related to ovarian clear cell carcinoma and clear cell adenocarcinoma. An important gene associated with Epithelial-Myoepithelial Carcinoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Glioma and Gastric cancer. The drugs Lenograstim and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and ovary, and related phenotypes are Increased proliferation and homeostasis/metabolism

Wikipedia : 73 Epithelial-myoepithelial carcinoma (EMCa) is a rare malignant tumour that typically arises in a salivary... more...

Related Diseases for Epithelial-Myoepithelial Carcinoma

Diseases related to Epithelial-Myoepithelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 660)
# Related Disease Score Top Affiliating Genes
1 ovarian clear cell carcinoma 32.4 TP53 PIK3CA KRT7
2 clear cell adenocarcinoma 32.2 TP53 PIK3CA KRT7
3 clear cell renal cell carcinoma 31.4 VIM TP53 PLIN2 KRT7 AKT1
4 polymorphous low-grade adenocarcinoma 30.8 VIM ACTC1
5 glycogen-rich clear cell breast carcinoma 30.7 KRT14 ACTC1
6 angiomyolipoma 30.7 VIM KRT7 ACTC1
7 oncocytoma 30.7 VIM KRT7 KRT14
8 adenofibroma 30.7 VIM TP53 KRT7 ACTC1
9 appendix adenocarcinoma 30.6 KRT7 HRAS
10 pleomorphic adenoma carcinoma 30.6 TP53 PLAG1 HMGA2
11 endometrioid ovary carcinoma 30.6 TP53 PIK3CA
12 salivary gland carcinoma 30.5 TP53 PLAG1 KRT7
13 mucoepidermoid carcinoma 30.5 TP53 KRT7 KRT14 HMGA2
14 lymphangiectasis 30.4 VIM ACTC1
15 mucinous adenocarcinoma 30.4 VIM TP53 KRT7
16 leiomyoma 30.4 VIM HMGA2 ACTC1
17 renal oncocytoma 30.3 VIM KRT7 KRT14
18 spindle cell sarcoma 30.3 VIM KRT7 ACTC1
19 collecting duct carcinoma 30.3 VIM SMARCB1 KRT7
20 reticulum cell sarcoma 30.3 VIM ACTC1
21 neurofibroma 30.2 VIM TP53 ACTC1
22 fibroma 30.2 VIM KRT14 ACTC1
23 secretory meningioma 30.2 VIM SMARCB1 KRT7
24 myoepithelial carcinoma 30.2 VIM TP53 SMARCB1 PLAG1 PIK3CA KRT7
25 cervical adenocarcinoma 30.2 TP53 KRT7 AKT1
26 papillary adenocarcinoma 30.2 VIM TP53 KRT7
27 endometrial adenocarcinoma 30.2 TP53 KRT7 AKT1
28 kidney cancer 30.2 TP53 PLIN2 PIK3CA AKT1
29 myoepithelioma 30.2 VIM SMARCB1 PLAG1 KRT14 ACTC1
30 breast fibroadenoma 30.2 TP53 KRT14 HMGA2
31 mucinous cystadenocarcinoma 30.2 VIM KRT7 ACTC1
32 adenosquamous carcinoma 30.1 TP53 PIK3CA KRT7
33 penile cancer 30.1 TP53 PIK3CA HRAS
34 rhabdoid meningioma 30.1 VIM SMARCB1
35 pleomorphic adenoma 30.1 VIM TP53 PLAG1 KRT7 KRT14 HRAS
36 squamous cell papilloma 30.1 TP53 KRT14 HRAS
37 necrotizing sialometaplasia 30.0 TP53 KRT7 ACTC1
38 lynch syndrome 30.0 TP53 PIK3CA HRAS AKT1
39 sebaceous adenocarcinoma 30.0 TP53 PLIN2 PLIN1 KRT14
40 adenoma 30.0 TP53 PLAG1 PIK3CA KRT7 AKT1
41 adrenal cortical carcinoma 29.9 VIM TP53 PIK3CA
42 spiradenoma 29.8 VIM TP53 KRT7 KRT14 ACTC1
43 serous cystadenocarcinoma 29.8 TP53 PIK3CA HRAS FBXW7 AKT1
44 lymphangioma 29.8 VIM TP53 PIK3CA HRAS ACTC1
45 endometrial serous adenocarcinoma 29.8 TP53 PIK3CA FBXW7
46 keratosis 29.7 TP53 PIK3CA KRT14 HRAS
47 endocervical adenocarcinoma 29.7 VIM TP53 PIK3CA KRT7
48 teratoma 29.6 TP53 SMARCB1 KRT7 AKT1 ACTC1
49 gallbladder cancer 29.5 TP53 PIK3CA KRT7 AKT1
50 hemangioma 29.5 VIM TP53 KRT7 AKT1 ACTC1

Graphical network of the top 20 diseases related to Epithelial-Myoepithelial Carcinoma:



Diseases related to Epithelial-Myoepithelial Carcinoma

Symptoms & Phenotypes for Epithelial-Myoepithelial Carcinoma

GenomeRNAi Phenotypes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 SMARCB1 TP53

MGI Mouse Phenotypes related to Epithelial-Myoepithelial Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 ACTC1 AKT1 FBXW7 HRAS KRT14 KRT7
2 growth/size/body region MP:0005378 10.14 ACTC1 AKT1 FBXW7 HRAS KRT14 PIK3CA
3 embryo MP:0005380 10.06 ACTC1 AKT1 FBXW7 PIK3CA PLAG1 SMARCB1
4 endocrine/exocrine gland MP:0005379 10.03 AKT1 FBXW7 HRAS KRT14 PIK3CA PLAG1
5 integument MP:0010771 9.97 AKT1 FBXW7 HRAS KRT14 PIK3CA PLIN1
6 muscle MP:0005369 9.86 ACTC1 AKT1 HRAS PIK3CA PLIN1 SMARCB1
7 neoplasm MP:0002006 9.7 AKT1 FBXW7 HRAS KRT14 PIK3CA SMARCB1
8 reproductive system MP:0005389 9.56 AKT1 KRT14 PIK3CA PLAG1 PLIN2 SMARCB1
9 vision/eye MP:0005391 9.23 FBXW7 KRT14 PIK3CA PLAG1 PLIN2 SMARCB1

Drugs & Therapeutics for Epithelial-Myoepithelial Carcinoma

Drugs for Epithelial-Myoepithelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
3
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
4
Gemcitabine Approved Phase 3 95058-81-4 60750
5
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
6
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
9
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
10
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
11 Carotenoids Phase 3
12 Adjuvants, Immunologic Phase 3
13 Antimetabolites Phase 3
14 Immunosuppressive Agents Phase 3
15 Antiviral Agents Phase 3
16 Anti-Infective Agents Phase 3
17 Hypoglycemic Agents Phase 2, Phase 3
18 taxane Phase 3
19 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
20 Tin Fluorides Phase 3
21
Vinblastine Approved Phase 2 865-21-4 13342 241903
22
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
23
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
24
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
25
Nintedanib Approved Phase 2 656247-17-5 56843413
26
Bevacizumab Approved, Investigational Phase 2 216974-75-3
27
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
28
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
29
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Ipilimumab Approved Phase 2 477202-00-9
32
nivolumab Approved Phase 2 946414-94-4
33
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
34
Iodine Approved, Investigational Phase 2 7553-56-2 807
35
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
36
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
37
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
40
Durvalumab Approved, Investigational Phase 2 1428935-60-7
41
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
42
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
43
Olaparib Approved Phase 2 763113-22-0 23725625
44
Lenvatinib Approved, Investigational Phase 2 417716-92-8
45
Pembrolizumab Approved Phase 2 1374853-91-4
46
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
47
Tremelimumab Investigational Phase 2 745013-59-6
48
Trebananib Investigational Phase 2 894356-79-7
49
Entinostat Investigational Phase 1, Phase 2 209783-80-2
50
Cediranib Investigational Phase 2 288383-20-0 9933475

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Unknown status NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
2 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
3 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
4 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
5 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
6 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
7 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
8 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
9 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
10 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
11 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
12 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
13 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
14 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
15 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
16 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
17 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients Not yet recruiting NCT04227522 Phase 3 Rucaparib;Placebos
18 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Unknown status NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
19 A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Unknown status NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
20 Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
21 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
22 Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas Completed NCT01914510 Phase 2 ENMD-2076
23 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
24 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
25 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
26 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
27 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
28 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
29 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
30 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
31 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
32 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
33 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
34 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
35 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Completed NCT00979992 Phase 2 Sunitinib Malate
36 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
37 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
38 A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
39 A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
40 A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
41 Phase II Study to Evaluate Efficacy and Safety of Sunitinib Therapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment (INMUNOSUN Study) Completed NCT03066427 Phase 2 Sunitinib
42 A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA) Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
43 Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma Recruiting NCT04735861 Phase 2 Sintilimab;Bevacizumab Biosimilar IBI305
44 BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
45 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
46 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
47 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
48 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
49 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
50 A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers Recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib

Search NIH Clinical Center for Epithelial-Myoepithelial Carcinoma

Genetic Tests for Epithelial-Myoepithelial Carcinoma

Anatomical Context for Epithelial-Myoepithelial Carcinoma

MalaCards organs/tissues related to Epithelial-Myoepithelial Carcinoma:

40
Salivary Gland, Breast, Ovary, Lung, Thyroid, Kidney, Skin

Publications for Epithelial-Myoepithelial Carcinoma

Articles related to Epithelial-Myoepithelial Carcinoma:

(show top 50) (show all 433)
# Title Authors PMID Year
1
Early stage clear cell adenocarcinoma coexisting with tubular adenoma and adenoma with clear cell change in the colon. 61
33420668 2021
2
The Myoepithelial Cells of Salivary Intercalated Duct-type Intraductal Carcinoma Are Neoplastic: A Study Using Combined Whole-slide Imaging, Immunofluorescence, and RET Fluorescence In Situ Hybridization. 61
33086236 2021
3
Epithelial-Myoepithelial Carcinoma. 61
33526226 2021
4
Recent updates in salivary gland tumors of the lung. 61
33744018 2021
5
Basal Cell Adenoma and Basal Cell Adenocarcinoma. 61
33526221 2021
6
The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. 61
33481388 2021
7
Primary salivary gland tumors of the lung: Two cases date report and literature review. 61
33457200 2021
8
Metastatic Epithelial-Myoepithelial Carcinoma in a Female Presenting with Neck Mass and Lytic Lesion in Acetabulum: A Diagnostic Challenge on Cytology. 61
32779157 2021
9
Epithelial-myoepithelial carcinoma at the base of the tongue presented with metastatic disease in the absence of myoepithelial anaplasia. 61
33380686 2020
10
Sebaceous Epithelial-Myoepithelial Carcinoma With Aggressive Behavior and Evidence of Preexisting Pleomorphic Adenoma. 61
33319619 2020
11
p16 Immunoexpression in sinonasal and nasopharyngeal adenoid cystic carcinomas: a potential pitfall in ruling out HPV-related multiphenotypic sinonasal carcinoma. 61
32671903 2020
12
Epithelial-Myoepithelial Carcinoma of the Lacrimal Gland: Case Report of Youngest Patient. 61
32332692 2020
13
First reported case of penile epithelial-myoepithelial carcinoma. 61
33102116 2020
14
Epithelial-myoepithelial carcinoma of the parotid gland with primary lung cancer: A rare case report. 61
33019442 2020
15
Clinical and pathological analysis of 10 cases of salivary gland epithelial-myoepithelial carcinoma. 61
33031333 2020
16
Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma. 61
32645560 2020
17
[Pulmonary Epithelial-myoepithelial Carcinoma;Report of a Case]. 61
32879278 2020
18
Water clear cell adenoma of parathyroid gland: a rare lesion. 61
32996732 2020
19
Pulmonary epithelial-myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report. 61
32859224 2020
20
Clinical outcomes and the role of bronchoscopic intervention in patients with primary pulmonary salivary gland-type tumors. 61
32512274 2020
21
Epithelial-myoepithelial carcinoma ex-pleomorphic adenoma of the parotid gland: report of a rare case with immunohistochemical and genetic analyses. 61
32749544 2020
22
Does Nodal Metastasis and Perineural Invasion Affect Local Control in Hyalinizing Clear Cell Carcinoma of the Oral Cavity? A Case Report with Long Term Follow-Up. 61
32720034 2020
23
Cytologic grading of primary malignant salivary gland tumors: A blinded review by an international panel. 61
32267606 2020
24
Primary epithelial-myoepithelial carcinoma of the pituitary gland. 61
31900996 2020
25
Primary Cutaneous Adenomyoepithelioma Ex Spiradenoma With Malignant Histologic Features, Epithelial-Myoepithelial Carcinoma Type: A First Case Report With Molecular Studies. 61
31813296 2020
26
New Insights into Tumor Heterogeneity: A Case of Solid-Oncocytic Epithelial-Myoepithelial Carcinoma of the Parotid Gland Harboring a HRAS and Heterogeneous Terminating ARID1A Mutation. 61
31309433 2020
27
Epithelial-Myoepithelial Carcinoma Of The Base Of Tongue. 61
32487431 2020
28
Salivary Duct Carcinoma of the Parotid Gland Originating from an Epithelial-Myoepithelial Carcinoma: Report of a Rare Case. 61
30937832 2020
29
Epithelial myoepithelial carcinoma of the parotid gland: A rare tumor with oncocytic changes. 61
32031104 2020
30
[A Rare Case of Pulmonary Epithelial-myoepithelial Carcinoma: Case Report and Literature Review]. 61
32093457 2020
31
A multicentre retrospective clinico-histopathological review of 250 patients after parotidectomy. 61
31375455 2020
32
Epithelial-myoepithelial carcinoma on lower lip and microinvasive verrucous carcinoma in vocal cord: Case report. 61
32259043 2020
33
Epithelial-Myoepithelial Carcinoma of the Lacrimal Sac and Literature Review of the Lacrimal System. 61
32341837 2020
34
Epithelial-myoepithelial carcinoma originating from a minor salivary gland in the nasal septum: A case report and literature review. 61
32000457 2020
35
Rare Development of Primary Parotid Gland Epithelial-Myoepithelial Carcinoma in a Child. 61
32665872 2020
36
Fine-needle aspiration cytology of the apocrine variant of epithelial-myoepithelial carcinoma. 61
31433568 2020
37
Bronchoscopic management of a primary endobronchial salivary epithelial-myoepithelial carcinoma: A case report. 61
32435581 2020
38
Epithelial-Myoepithelial Carcinoma of the Palate: Report of a Case and Review of the Literatures. 61
32215030 2020
39
Epithelial-Myoepithelial Carcinoma of the Breast with Rhabdoid Features. 61
33083078 2020
40
Sclerosing pneumocytoma mixed with a columnar clear cell adenoma and a typical carcinoid: case report and review of literature. 61
33165428 2020
41
Epithelial membrane antigen and DOG1 expression in minor salivary gland tumours. 61
31629156 2019
42
Utility of neck dissection for management of carcinoma of the parotid gland. 61
31564483 2019
43
Primary salivary gland-type tumors of the tracheobronchial tree diagnosed by transbronchial fine needle aspiration: Clinical and cytomorphologic features with histopathologic correlation. 61
31343850 2019
44
Apocrine epithelial-myoepithelial carcinoma of the parotid gland with concurrent oncocytic change: a novel variant. 61
31078503 2019
45
Epithelial-myoepithelial carcinoma of the breast: A rare type of malignant adenomyoepithelioma. 61
31310415 2019
46
Epithelial Myoepithelial Carcinoma of Parotid Gland. 61
31741932 2019
47
A first case report of primary epithelial myoepithelial carcinoma-like renal tumor showing a perivascular pseudorosette-like pattern: Description of morphologic, immunohistochemical, and genetic features. 61
31574838 2019
48
Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic Spectrum. 61
30994537 2019
49
Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma. 61
31094929 2019
50
Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing. 61
30585117 2019

Variations for Epithelial-Myoepithelial Carcinoma

Cosmic variations for Epithelial-Myoepithelial Carcinoma:

9 (show top 50) (show all 998)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM145017479 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 4
2 COSM144087035 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Y61C 17:7674872-7674872 4
3 COSM93183448 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
4 COSM111758374 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
5 COSM122271391 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.263A>G p.Y88C 17:7674872-7674872 4
6 COSM143156731 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Y61C 17:7674872-7674872 4
7 COSM144650895 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 4
8 COSM106053037 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
9 COSM105620035 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
10 COSM112253220 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
11 COSM143943655 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Y61C 17:7674872-7674872 4
12 COSM144310046 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 4
13 COSM142560073 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 4
14 COSM142837225 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
15 COSM122734046 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.263A>G p.Y88C 17:7674872-7674872 4
16 COSM87897883 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 4
17 COSM121875754 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.263A>G p.Y88C 17:7674872-7674872 4
18 COSM144013214 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.626A>G p.Y209C 17:7674872-7674872 4
19 COSM143370705 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 4
20 COSM148933502 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.*225G>C p.? 3:179234302-179234302 4
21 COSM87133148 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.3145G>C p.G1049R 3:179234302-179234302 4
22 COSM87135928 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.331A>G p.K111E 3:179199156-179199156 4
23 COSM148936463 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.331A>G p.K111E 3:179199156-179199156 4
24 COSM103028523 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 4
25 COSM98760930 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 4
26 COSM98832818 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 4
27 COSM98771857 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.332T>A p.L111* 23:53217863-53217863 4
28 COSM111443773 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.254T>A p.L85* 23:53217863-53217863 4
29 COSM105721394 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Q61R 11:533874-533874 4
30 COSM112988925 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
31 COSM101951686 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
32 COSM91331243 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
33 COSM105721476 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
34 COSM101967342 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 4
35 COSM151592898 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
36 COSM149960989 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
37 COSM150962667 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
38 COSM151345966 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
39 COSM151492854 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
40 COSM146246972 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
41 COSM110182063 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
42 COSM151326946 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 4
43 COSM150312692 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
44 COSM102381853 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
45 COSM102453467 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
46 COSM150277642 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
47 COSM150815521 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
48 COSM150455095 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
49 COSM151309497 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4
50 COSM150915108 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 4

Expression for Epithelial-Myoepithelial Carcinoma

Search GEO for disease gene expression data for Epithelial-Myoepithelial Carcinoma.

Pathways for Epithelial-Myoepithelial Carcinoma

Pathways related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 TP53 PIK3CA HRAS AKT1
2
Show member pathways
12.62 TP53 SMARCB1 PIK3CA HRAS AKT1
3
Show member pathways
12.54 VIM PIK3CA HRAS AKT1
4
Show member pathways
12.53 TP53 PIK3CA HRAS AKT1
5
Show member pathways
12.45 TP53 PIK3CA HRAS AKT1
6
Show member pathways
12.44 TP53 PIK3CA HRAS AKT1
7
Show member pathways
12.43 TP53 PIK3CA HRAS AKT1
8
Show member pathways
12.38 TP53 PIK3CA HRAS AKT1
9
Show member pathways
12.32 TP53 PIK3CA HRAS AKT1
10 12.26 VIM TP53 PIK3CA HRAS HMGA2
11
Show member pathways
12.25 TP53 PIK3CA HRAS AKT1
12 12.25 TP53 PIK3CA HRAS AKT1
13
Show member pathways
12.22 TP53 PIK3CA HRAS AKT1
14 12.2 TP53 PIK3CA HRAS AKT1
15
Show member pathways
12.18 PIK3CA HRAS AKT1
16
Show member pathways
12.17 TP53 PIK3CA HRAS AKT1
17
Show member pathways
12.04 PIK3CA HRAS AKT1
18 12.04 PIK3CA HRAS AKT1
19
Show member pathways
12.04 TP53 PIK3CA HRAS AKT1
20 12.03 PLIN1 HRAS AKT1
21
Show member pathways
12.02 PIK3CA HRAS AKT1
22 12.02 TP53 PIK3CA HRAS AKT1
23
Show member pathways
11.99 TP53 PIK3CA HRAS AKT1
24
Show member pathways
11.98 PIK3CA HRAS AKT1
25
Show member pathways
11.98 TP53 PIK3CA AKT1
26 11.94 VIM TP53 AKT1
27 11.94 PIK3CA KRT14 HRAS AKT1
28 11.92 TP53 HRAS AKT1
29
Show member pathways
11.9 VIM KRT7 KRT14
30 11.87 PIK3CA HRAS AKT1
31 11.82 TP53 PIK3CA AKT1
32
Show member pathways
11.82 PIK3CA HRAS AKT1
33 11.79 TP53 PIK3CA HRAS AKT1
34 11.76 TP53 KRT14 AKT1
35
Show member pathways
11.76 PIK3CA HRAS AKT1
36 11.7 TP53 PIK3CA HRAS AKT1
37 11.69 TP53 PIK3CA AKT1
38 11.68 PIK3CA HRAS AKT1
39 11.66 PIK3CA HRAS AKT1
40 11.65 PIK3CA HRAS AKT1
41 11.64 PIK3CA HRAS AKT1
42 11.62 PIK3CA HRAS AKT1
43 11.62 TP53 PIK3CA HRAS AKT1
44
Show member pathways
11.61 TP53 PIK3CA AKT1
45 11.59 PIK3CA HRAS AKT1
46
Show member pathways
11.57 PIK3CA HRAS AKT1
47 11.52 PLIN1 PIK3CA AKT1
48 11.48 PIK3CA HRAS AKT1
49 11.48 TP53 PIK3CA AKT1
50 11.36 PIK3CA HRAS AKT1

GO Terms for Epithelial-Myoepithelial Carcinoma

Cellular components related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.7 VIM TP53 SMARCB1 PLIN2 PLAG1 KRT7
2 cytosol GO:0005829 9.4 VIM TP53 PLIN2 PLIN1 PLAG1 PIK3CA

Biological processes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 TP53 SMARCB1 PLAG1 HRAS HMGA2 AKT1
2 cytokine-mediated signaling pathway GO:0019221 9.56 VIM TP53 PIK3CA AKT1
3 viral process GO:0016032 9.55 VIM TP53 SMARCB1 KRT7 FBXW7
4 negative regulation of macroautophagy GO:0016242 9.4 PIK3CA AKT1
5 anoikis GO:0043276 9.37 PIK3CA AKT1
6 negative regulation of gene expression GO:0010629 9.35 TP53 PLAG1 HRAS FBXW7 AKT1
7 positive regulation of gene expression GO:0010628 9.17 VIM TP53 PLAG1 HRAS HMGA2 AKT1

Molecular functions related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament binding GO:1990254 8.62 VIM KRT14

Sources for Epithelial-Myoepithelial Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....